Literature DB >> 11123290

IL-7 enhances the responsiveness of human T cells that develop in the bone marrow of athymic mice.

E C Tsark1, M A Dao, X Wang, K Weinberg, J A Nolta.   

Abstract

The beige/nude/xid/human (bnx/hu) model of human hematopoiesis provides a unique opportunity to study extrathymic human T lymphocyte development in an in vivo system. Purified human hematopoietic stem cells develop into mature T lymphocytes and immature progenitors in the bone marrow of athymic bnx mice. The human T cells are all TCR alpha beta(+) and display a restricted TCRV beta repertoire. In the current studies, we examined the effects of systemic human IL-7 (huIL-7) administration on the phenotype and the activation status of the bnx/hu T cells. In the majority of the mice that did not have huIL-7 administration, a higher frequency of human CD3(+)/CD8(+) than CD3(+)/CD4(+) T cells developed in the bone marrow. This phenomenon is also frequently observed in human bone marrow transplant recipients. Extremely low levels of IL-2 were expressed by human CD3(+) cells isolated from these mice, in response to PMA plus ionomycin and to CD3 and CD28 cross-linking. IL-4 was not expressed by cells exposed to either stimulus, demonstrating a profound inability of the bnx/hu T cells to produce this cytokine. Systemic production of huIL-7 from engineered stromal cells transplanted into the mice increased the human CD4 to CD8 ratios, and increased the ratio of memory to naive CD4(+) and CD8(+) T cells. The human CD3(+) cells recovered from mice that had systemic huIL-7 and equivalent numbers of CD3(+)/CD4(+) and CD3(+)/CD8(+) cells in the marrow were still unable to produce IL-4 in response to any condition tested, but were capable of normal levels of IL-2 production following stimulation.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11123290     DOI: 10.4049/jimmunol.166.1.170

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  10 in total

Review 1.  Mesenchymal stem cells for the sustained in vivo delivery of bioactive factors.

Authors:  Todd Meyerrose; Scott Olson; Suzanne Pontow; Stefanos Kalomoiris; Yunjoon Jung; Geralyn Annett; Gerhard Bauer; Jan A Nolta
Journal:  Adv Drug Deliv Rev       Date:  2010-10-13       Impact factor: 15.470

Review 2.  Mesenchymal stem cells for the treatment of neurodegenerative disease.

Authors:  Nanette Joyce; Geralyn Annett; Louisa Wirthlin; Scott Olson; Gerhard Bauer; Jan A Nolta
Journal:  Regen Med       Date:  2010-11       Impact factor: 3.806

Review 3.  New approaches for preventing and treating chronic graft-versus-host disease.

Authors:  Stephanie J Lee
Journal:  Blood       Date:  2005-02-08       Impact factor: 22.113

4.  T lymphoid differentiation in human bone marrow.

Authors:  Florian Klein; Niklas Feldhahn; Sanggyu Lee; Hui Wang; Fiammetta Ciuffi; Mirko von Elstermann; María L Toribio; Heinrich Sauer; Maria Wartenberg; Varun Singh Barath; Martin Krönke; Peter Wernet; Janet D Rowley; Markus Müschen
Journal:  Proc Natl Acad Sci U S A       Date:  2003-05-08       Impact factor: 11.205

5.  In vivo biosafety model to assess the risk of adverse events from retroviral and lentiviral vectors.

Authors:  Gerhard Bauer; Mo A Dao; Scott S Case; Todd Meyerrose; Louisa Wirthlin; Ping Zhou; Xiuli Wang; Phillip Herrbrich; Jesusa Arevalo; Susie Csik; Dianne C Skelton; Jon Walker; Karen Pepper; Donald B Kohn; Jan A Nolta
Journal:  Mol Ther       Date:  2008-05-06       Impact factor: 11.454

6.  Albumin-expressing hepatocyte-like cells develop in the livers of immune-deficient mice that received transplants of highly purified human hematopoietic stem cells.

Authors:  Xiuli Wang; Shundi Ge; George McNamara; Qian-Lin Hao; Gay M Crooks; Jan A Nolta
Journal:  Blood       Date:  2003-01-30       Impact factor: 22.113

7.  Mesenchymal stem cells for trinucleotide repeat disorders.

Authors:  Geralyn Annett; Gerhard Bauer; Jan A Nolta
Journal:  Methods Mol Biol       Date:  2013

Review 8.  Genetically engineered mesenchymal stem cells as a proposed therapeutic for Huntington's disease.

Authors:  Scott D Olson; Kari Pollock; Amal Kambal; Whitney Cary; Gaela-Marie Mitchell; Jeremy Tempkin; Heather Stewart; Jeannine McGee; Gerhard Bauer; Hyun Sook Kim; Teresa Tempkin; Vicki Wheelock; Geralyn Annett; Gary Dunbar; Jan A Nolta
Journal:  Mol Neurobiol       Date:  2011-12-09       Impact factor: 5.590

9.  Geographic clonal tracking in macaques provides insights into HSPC migration and differentiation.

Authors:  Chuanfeng Wu; Diego A Espinoza; Samson J Koelle; E Lake Potter; Rong Lu; Brian Li; Di Yang; Xing Fan; Robert E Donahue; Mario Roederer; Cynthia E Dunbar
Journal:  J Exp Med       Date:  2017-11-15       Impact factor: 14.307

Review 10.  Contribution of human hematopoietic stem cells to liver repair.

Authors:  Ping Zhou; Louisa Wirthlin; Jeannine McGee; Geralyn Annett; Jan Nolta
Journal:  Semin Immunopathol       Date:  2009-06-17       Impact factor: 9.623

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.